5-HT(2B) receptors play a key role in mediating the excitatory effects of 5-HT in human colon in vitro
- PMID:11877320
- PMCID: PMC1573235
- DOI: 10.1038/sj.bjp.0704571
5-HT(2B) receptors play a key role in mediating the excitatory effects of 5-HT in human colon in vitro
Abstract
1. 5-Hydroxytryptamine (5-HT) is known to produce a number of different effects in the gastrointestinal tract of various species, and has been proposed to play a key role in a number of intestinal disorders in man, including irritable bowel syndrome (IBS), although the receptors involved have yet to be established. The aim of the present study was to investigate the distribution and function of 5-HT(2B) receptors in human colon, and to establish their possible role in the aetiology of IBS. 2. The distribution of 5-HT(2B) receptor mRNA and protein were investigated by quantitative RT - PCR, Western analysis and immunocytochemistry. High levels of both mRNA and protein for 5-HT(2B) receptors were found throughout the human gastrointestinal tract, and in particular in colon, where 5-HT(2B) receptors were found predominantly in the longitudinal and circular smooth muscle layers within the muscularis externa, and in the myenteric nerve plexus lying between these two layers. 3. Electrical field stimulation of longitudinal muscle preparations of human colon mounted in organ baths resulted in neuronally-mediated contractile responses, that were significantly potentiated by application of 5-HT (up to 10(-7) M), with a pEC(50) of 8.2 +/- 0.1 (n=49 donors). The response to 5-HT was inhibited by a number of selective 5-HT(2B) receptor antagonists. 4. This study has shown for the first time that, in contrast to animal studies, the excitatory effects of 5-HT in human colon are mediated by 5-HT(2B) receptors. It is proposed that these receptors contribute to the putative 5-HT-induced colonic smooth muscle hypersensitivity associated with IBS.
Figures








Similar articles
- Characterization of the receptors involved in the 5-HT-induced excitation of canine antral longitudinal muscle.Prins NH, Akkermans LM, Lefebvre RA, Schuurkes JA.Prins NH, et al.Br J Pharmacol. 2001 Nov;134(6):1351-9. doi: 10.1038/sj.bjp.0704376.Br J Pharmacol. 2001.PMID:11704657Free PMC article.
- Cisapride and 5-hydroxytryptamine enhance motility in the canine antrum via separate pathways, not involving 5-hydroxytryptamine1,2,3,4 receptors.de Ridder WJ, Schuurkes JA.de Ridder WJ, et al.J Pharmacol Exp Ther. 1993 Jan;264(1):79-88.J Pharmacol Exp Ther. 1993.PMID:8093733
- Characterization of 5-hydroxytryptamine (5-HT) receptor subtypes influencing colonic motility in conscious dogs.Nagakura Y, Kamato T, Nishida A, Ito H, Yamano M, Miyata K.Nagakura Y, et al.Naunyn Schmiedebergs Arch Pharmacol. 1996 Apr;353(5):489-98. doi: 10.1007/BF00169167.Naunyn Schmiedebergs Arch Pharmacol. 1996.PMID:8740141
- Review article: serotonin receptors and transporters -- roles in normal and abnormal gastrointestinal motility.Gershon MD.Gershon MD.Aliment Pharmacol Ther. 2004 Nov;20 Suppl 7:3-14. doi: 10.1111/j.1365-2036.2004.02180.x.Aliment Pharmacol Ther. 2004.PMID:15521849Review.
- Irritable bowel syndrome: new agents targeting serotonin receptor subtypes.De Ponti F, Tonini M.De Ponti F, et al.Drugs. 2001;61(3):317-32. doi: 10.2165/00003495-200161030-00001.Drugs. 2001.PMID:11293643Review.
Cited by
- Spasmolytic Effects of Aphanizomenon Flos Aquae (AFA) Extract on the Human Colon Contractility.Amato A, Terzo S, Marchesa P, Maffongelli A, Martorana M, Scoglio S, Mulè F.Amato A, et al.Nutrients. 2021 Sep 28;13(10):3445. doi: 10.3390/nu13103445.Nutrients. 2021.PMID:34684446Free PMC article.
- Expression of the serotonin receptor 2B in uveal melanoma and effects of an antagonist on cell lines.Weidmann C, Bérubé J, Piquet L, de la Fouchardière A, Landreville S.Weidmann C, et al.Clin Exp Metastasis. 2018 Mar;35(3):123-134. doi: 10.1007/s10585-018-9894-x. Epub 2018 Apr 25.Clin Exp Metastasis. 2018.PMID:29696577
- Serotonergic Control of Gastrointestinal Development, Motility, and Inflammation.Najjar SA, Hung LY, Margolis KG.Najjar SA, et al.Compr Physiol. 2023 Jun 26;13(3):4851-4868. doi: 10.1002/cphy.c220024.Compr Physiol. 2023.PMID:37358510Free PMC article.
- Treating irritable bowel syndrome: overview, perspective and future therapies.Camilleri M.Camilleri M.Br J Pharmacol. 2004 Apr;141(8):1237-48. doi: 10.1038/sj.bjp.0705741. Epub 2004 Mar 22.Br J Pharmacol. 2004.PMID:15037521Free PMC article.Review.
- Pharmacophore-based tailoring of biphenyl amide derivatives as selective 5-hydroxytryptamine 2B receptor antagonists.Gabr MT, Abdel-Raziq MS.Gabr MT, et al.Medchemcomm. 2018 May 21;9(6):1069-1075. doi: 10.1039/c8md00204e. eCollection 2018 Jun 1.Medchemcomm. 2018.PMID:30108996Free PMC article.
References
- BONHAUS D.W., FLIPPIN L.A., GREENHOUSE R.J., JAIME S., ROCHA C., DAWSON M., VAN NATTA K., CHANG L.K., PULIDO-RIOS T., WEBBER A., LEUNG E., EGLEN R.M., MARTIN G.R. RS-127445: a selective, high affinity, orally bioavailable 5-HT2B receptor antagonist. Br. J. Pharmacol. 1999;127:1075–1082. - PMC - PubMed
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases